Astex ( Astex)

Primary tabs

Astex's picture

Management

Contact Address

About Astex

Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.

Astex press release, blog etc

Sat, 12/31/2022 - 01:31 Astex Co-founder and CEO Harren Jhoti Awarded OBE in the Kings New Year Honours
Wed, 04/14/2021 - 13:22 NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology
Tue, 09/03/2019 - 18:22 Astex Pharmaceuticals announces that its novel, oral hypomethylating agent ASTX727 has been granted orphan drug designation for the treatment of myelodysplastic syndromes (including chronic myelomonocytic leukemia) by the US FDA
Fri, 06/07/2019 - 05:38 Taiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals Drug Candidates
Thu, 06/06/2019 - 21:34 British Company Behind Groundbreaking Breast Cancer Treatment
Fri, 04/12/2019 - 16:27 Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval
Mon, 07/30/2018 - 03:07 Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naive AML patients ineligible to receive intense induction chemotherapy
Wed, 05/09/2018 - 03:25 Astexs Harren Jhoti Made Fellow of the Royal Society
Thu, 03/15/2018 - 13:36 Astex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation
Fri, 01/26/2018 - 13:52 Harren Jhoti Receives Lifetime Achievement Award from the UK BioIndustry Association
Tue, 11/29/2016 - 10:40 Astex to Showcase Its Next-Generation Hypomethylating Agents Being Developed for Treatment of AML/MDS at the 2016 Annual Meeting of the American Society of Hematology
Mon, 11/21/2016 - 10:44 Astex Joins the Dementia Discovery Fund as a Strategic Investor
Tue, 11/01/2016 - 11:00 Astex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (ribociclib) plus letrozole as a first-line treatment for HR+/HER2- Advanced Breast Cancer

InfoBox

HomePagewww.astx.com